Coulter Partners successfully completed a search assignment for Tozaro and is pleased to announce the placement of Dr. Jason Slingsby, MBA as Chief Executive Officer.

Tozaro is a pioneering technology provider specializing in cell and gene therapy manufacturing. The company focuses on advancing its Smart Polymer technology to revolutionize downstream processing in this field. With a commitment to strategic growth and innovation, Tozaro aims to push the boundaries of what's possible in biological sciences.

Dr. Jason Slingsby brings over 20 years of expertise in biotech innovation, strategic growth, and commercialization within the life sciences sector. His career includes key leadership roles at LifeArc, Oxford Biomedica, and ProtAffin AG, where as CEO and Co-founder he successfully led business development, M&A strategies, and secured significant funding. At Tozaro, Dr. Slingsby will spearhead the commercialization of the company’s Smart Polymer technology, aiming to redefine downstream processing in cell and gene therapies while driving strategic growth and innovation.

Commenting on his appointment, Dr. Jason Slingsby, new CEO of Tozaro, said: “Tozaro is an exciting company in the cell and gene therapy manufacturing technology space, and I look forward to working with the team to continue to build value, forge new partnerships and strengthen our position as innovators. Tozaro’s Smart Polymer technology holds the potential to redefine how we approach downstream processing of cell and gene therapies. I look forward to leading the company through this commercialization phase, allowing our partners to go beyond the limits of what was previously thought possible in biology.”

Dr. Mark Payton, CEO of Mercia Asset Management PLC and Non-Executive Director of Tozaro, added: " We are delighted to welcome Jason to the board as Tozaro’s CEO. His team philosophy and track record of driving strategic growth, innovation, and operational excellence make him the ideal leader to take Tozaro into its next chapter.”

----

Dr. Jason Slingsby, MBA, CEO of Tozaro

Dr. Jason Slingsby is a biotech leader with over two decades of experience in driving innovation, strategic growth, and commercialization within the life sciences industry. His career includes key leadership roles that have shaped the trajectory of renowned organizations. As Chief Business Officer at LifeArc, he spearheaded business development, alliance management, funding, and technology transfer efforts, fostering impactful partnerships. His tenure as Chief Business and Corporate Development Officer at OXB (previously Oxford Biomedica) saw him guiding M&A strategies and expanding the company’s reach into the US market. Moreover, as CEO and Co-founder of ProtAffin AG, Jason secured over £20 million in funding for the development of novel biologics, reinforcing his leadership in biotech innovation.

He holds an undergraduate degree in biochemistry from the University of Oxford, a PhD in genetics from Imperial College London, and an MBA with Distinction from London Business School.

About Tozaro

Tozaro is developing a novel suite of affinity reagents to help transform the development and manufacture of viral vectors in cell and gene therapy. Operating at the intersection of chemistry, computational biology and cell and gene therapy, Tozaro’s smart polymers are improving on current analytical and purification processes to realize a future where advanced therapies are more accessible to all.
Tozaro is partnering with leading companies in the cell and gene therapy sector to introduce novel synthetic affinity reagents, aligned to critical applications. The Company is backed by leading life sciences investor groups, including Mercia and Calculus Capital.

For more information, please visit www.tozaro.com

About Coulter Partners

We are executive search and leadership development specialists working to build a better future. As advisors and consultants to companies at the cutting edge of Health, Science, and Technology, we are united by our mission to build teams that change the world. Operating uniquely as one global team, we have honed our expertise, platform, and data for over two decades, working across three continents, and in 40 countries. Applying what we learn through our work with boards, leadership teams, and investors in the world’s most innovative companies, we bring together and develop the right people at the right time to propel them to achieve their worthwhile goals.

www.coulterpartners.com

Coulter Partners secures experienced biotech strategist as Tozaro CEO

About Tozaro

About Coulter Partners

Related

19th Bioshares Biotech Summit

#Twenty25 - Funding the future of health tech - Part 19/20 Interview with Inga Deakin, Molten Ventures

#Twenty25 - Funding the future of health tech - Part 18/20 Interview with Issy Gordon, Salica Investments

#Twenty25 - Funding the future of health tech - Part 17/20 Interview with Molly Gilmartin, AlbionVC